Filing Details

Accession Number:
0000899243-20-019873
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-21 19:39:10
Reporting Period:
2020-07-17
Accepted Time:
2020-07-21 19:39:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1807901 Pandion Therapeutics Inc. PAND () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1721017 Vikas Goyal C/O Pandion Therapeutics, Inc.,
134 Coolidge Avenue
Watertown MA 02472
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-07-21 7,044 $0.00 86,314 No 4 C Direct
Common Stock Acquisiton 2020-07-21 1,450 $18.00 87,764 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2020-07-17 3,806 $0.00 3,806 $18.00
Common Stock Stock Option (right to buy) Acquisiton 2020-07-17 13,935 $0.00 13,935 $18.00
Common Stock Stock Option (right to buy) Acquisiton 2020-07-17 10,486 $0.00 10,486 $18.00
Common Stock Series B Preferred Stock Disposition 2020-07-21 35,922 $0.00 7,044 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,806 2030-07-16 No 4 A Direct
13,935 2030-07-16 No 4 A Direct
10,486 2030-07-16 No 4 A Direct
0 No 4 C Direct
Footnotes
  1. The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. Represents shares purchased through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.
  3. This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on August 1, 2020, with the remainder of the shares vesting in equal monthly installments following August 1, 2020 through August 1, 2023, subject to the reporting person's continued service on each applicable vesting date.
  4. This option award was granted on July 17, 2020. 1/4 of the shares underlying the award shall vest on May 21, 2021, with the remainder of the shares vesting in equal monthly installments following May 21, 2021 through May 21, 2024, subject to the reporting person's continued service on each applicable vesting date.
  5. This option award was granted on June 25, 2020. 1/4 of the shares underlying the award shall vest on June 25, 2021, with the remainder of the shares vesting in equal monthly installments following June 25, 2021 through June 25, 2024, subject to the reporting person's continued service on each applicable vesting date.